Hemoperfusion treatment in a septic shock patient with autosomal dominant polycystic kidney disease and increased HMGB1 protein levels

Blood Purification

Volumn 32, Issue 2, 2011, Pages 139-142

  Nakamura, Tsukasa ^a   Kawagoe, Yasuhiro ^a   Ueda, Yoshihiko ^b   Yamada, Shingo ^c   Koide, Hikaru ^d  

^a Shinmatsudo Central General Hospital   (Japan)

^b DOKKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c SHINO TEST CORPORATION   (Japan)

^d KOTO HOSPITAL   (Japan)

Author keywords

Autosomal dominant polycystic kidney disease; Endotoxin; High mobility group box 1 protein; Polymyxin B immobilized fiber; Sepsis

Indexed keywords

C REACTIVE PROTEIN; CALCIUM; CREATININE; DOPAMINE; ENDOTOXIN; HEMOGLOBIN; HIGH MOBILITY GROUP B1 PROTEIN; IMMUNOGLOBULIN; POLYMYXIN B;

ABDOMINAL PAIN; ABDOMINAL RADIOGRAPHY; AGED; ARTICLE; BLOOD CULTURE; BLOOD FLOW VELOCITY; BODY TEMPERATURE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; ENDOTOXEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMORAL VEIN; FEVER; HEART RATE; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HEMOPERFUSION; HEPATOMEGALY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HUMAN CELL; INFORMED CONSENT; KIDNEY CYST; KIDNEY POLYCYSTIC DISEASE; KLEBSIELLA PNEUMONIAE; LEUKOCYTE COUNT; NONHUMAN; PRIORITY JOURNAL; PROTEINURIA; PSEUDOMONAS AERUGINOSA; PYELONEPHRITIS; SEPTIC SHOCK; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE; UREA NITROGEN BLOOD LEVEL; URINALYSIS;

AGED; ANTI-BACTERIAL AGENTS; BODY TEMPERATURE; C-REACTIVE PROTEIN; DICARBETHOXYDIHYDROCOLLIDINE; ENDOTOXINS; FEMALE; GAMMA-GLOBULINS; HEMOPERFUSION; HMGB1 PROTEIN; HUMANS; IMMOBILIZED PROTEINS; KLEBSIELLA PNEUMONIAE; LEUKOCYTE COUNT; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; POLYMYXIN B; PSEUDOMONAS AERUGINOSA; SHOCK, SEPTIC;

EID: 79957931902     PISSN: 02535068     EISSN: 14219735     Source Type: Journal    
DOI: 10.1159/000325731     Document Type: Article

References (18)

1. Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, Lentini P, Nalesso F, Ueno T, Ranieri VM, Ronco C: Effectiveness of polymyxin B-immobilized fiber column in sepsis: A systemic review. Crit Care 2007; 11:R47.
2. Shoji H: Extracorporeal endotoxin removed for the treatment of sepsis: Endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial 2003; 7: 108-114. (Pubitemid 36648053)
3. Yamada S, Maruyama I: HMGB1, a novel inflammatory cytokine. Clin Chim Acta 2007; 375: 36-42. (Pubitemid 44584241)
4. Sakamoto Y, Mashiko K, Matsumoto H, Hara Y, Kutsukawa N, Yamamoto Y: Relationship between effect of polymyxin B-immobilized fiber and high-mobility group box-1 protein in septic shock patients. ASAIO J 2007; 53: 324-328. (Pubitemid 46791540)
5. Gibot S, Massin F, Cravoisy A, Barraud D, Nace L, Levy B, Bollaert PE: High-mobility group box-1 protein plasma concentrations during septic shock. Int Care Med 2007; 33: 1347-1353. (Pubitemid 47101699)
6. Sakamoto Y, Mashiko K, Matsumoto H, Hara Y, Kutsukawa N, Takei K, Ueno Y, Tomita Y, Yamamoto Y: Effect of direct hemoperfusion with a polymyxin B-immobilized fiber column on high mobility group box-1 (HMGB1) in severe septic shock: Report of a case. ASAIO J 2006; 52:e37-e39. (Pubitemid 44784557)
7. Ravine D, Gibson RN, Walker RG, Shefield LJ, Kincaid-Smith P, Danks DM: Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease. Lancet 1994; 343: 824-827. (Pubitemid 24147512)
8. Aoki H, Kodama M, Tani T, Hanasawa K: Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber. Am J Surg 1994; 167: 412-417.
9. Yamada S, Yakabe K, Ishii J, Imaizumi H, Maruyama I: New high mobility group box 1 assay system. Clin Chim Acta 2006; 372: 173-178. (Pubitemid 44286776)
10. Nakamura T, Kawagoe Y, Matsuda T, Koide H: Effect of polymyxin B-immobilized fiber on bone resorption in patients with sepsis. Intens Care Med 2004; 30: 1838-1841. (Pubitemid 39297191)
11. Nakamura T, Suzuki T, Kawagoe Y, Koide H: Polymyxin B-immobilized fiber hemoperfusion attenuates increased plasma atrial natriuretic peptide and brain natriuretic peptide levels in patients with septic shock. ASAIO J 2008; 54: 210-213. (Pubitemid 351450769)
12. Torres VE, Rossetti S, Harris PC: Update on autosomal dominant polycystic kidney disease. Minerva Med 2007; 98: 669-691. (Pubitemid 351196059)
13. Gupta S, Seith A, Sud K, Kohli HS, Singh SK, Sakhaja V, Suri S: CT in the evaluation of complicated autosomal dominant polycystic kidney disease. Acta Radiol 2000; 41: 280-284.
14. Wang H, Li W, Goldstein R, Tracey KJ, Sama AE: HMGB1 as a potential therapeutic target. Novartis Found Symp 2007; 280: 73-85.
15. Hatada T, Wada H, Nobori T, Okabayashi K, Maruyama K, Abe Y, Uemoto S, Yamada S, Maruyama I: Plasma concentrations and importance of high mobility group box protein in the progress of organ failure in patients with disseminated intravascular coagulation. Thromb Haemost 2005; 94: 975-979. (Pubitemid 41645937)
16. Nakamura T, Kawagoe Y, Suzuki T, Shoji H, Ueda Y, Kobayashi N, Koide H: Changes in plasma IL-18 by direct hemoperfusion with polymyxin B-immobilized fiber in patients with septic shock. Blood Purif 2005; 23: 417-422.
17. Kanesaka S, Sasaki J, Kuzume M. Narihara K, Takahashi Y: Effect of direct hemoperfusion using polymyxin B immobilized fiber on inflammatory mediators in patients with severe sepsis and septic shock. Int J Artif Organs 2008; 31: 891-897.
18. Kumagai T, Takeyama N, Yabuki T, Harada M, Miki Y, Kanou H, Inoue S, Nakagawa T, Noguchi H: Apheresis of activated leukocytes with an immobilized polymyxin B filter in patients with septic shock. Shock 2010; 34: 461-466.